An observational study in Cervix Cancer, sponsored by Tata Memorial Hospital. Recruiting at 1 site in India. Open to female participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-02-20.
Sponsored by Tata Memorial Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital — 9 open to participants now, 9 under way, 1 of them phase 3. Uterine Cervical Neoplasms · Tata Memorial Hospital.
Among the 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital, this one has the largest planned enrollment of the 10 observational ones that give a count, is the only one that started in 2022, is one of 10 observational ones, and was the 20th registered.
2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.
Browse Uterine Cervical Neoplasms studies →9 of the 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital are open now, in 3 countries. Recruiting first, the newest first:
Tata Memorial Hospital · Sites in India, Japan, Thailand
Women only
Tata Memorial Hospital · Sites in India
Ages 18+ · Women only
Tata Memorial Hospital · Sites in India
Ages 18–75 · Women only
Tata Memorial Hospital · Sites in India
Ages 18–70 · Women only
Tata Memorial Hospital · Sites in India
By country, each count listing its studies:
Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.
This study: 18 Years to 90 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 1996; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,800 is above the median of 220 across 530 observational studies indexed under Uterine Cervical Neoplasms.
Median enrollment 316 across the 17 interventional studies, 325 across the 10 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Tata Memorial Hospital is the lead sponsor of 99 studies on the registry; 21 are open to participants now.
2 of the studies in Uterine Cervical Neoplasms by Tata Memorial Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06644846Tata Memorial HospitalSpatially Fractionated Radiation Treatment for Gynaecological Cancers | 2027-02-28 |
| NCT07400809Tata Memorial HospitalCervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study. | 2027-06-14 |
Add all 2 to your calendar (.ics) → With an account.
Among the 27 studies in Uterine Cervical Neoplasms by Tata Memorial Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Retrospective study utilizing patient data to develop and validate Machine Learning application. Available imaging data sets of patients who have completed treatment will be used to develop Normal tissue complication probability and Tumour control probability
Hypothesis Integrating existing radiation treatment information, quantitative imaging and patient outcome data from completed and ongoing clinical trials will allow development of knowledge based systems for efficient treatment delivery and allow selection of patients for intensified treatment approaches in cervix cancer.
For Aim 1. Automatic delineation of complex tumour targets for cervical cancer for the Gross Tumour Volume (GTV) at baseline and at brachytherapy and High Risk Clinical Target Volume(CTV) at baseline and brachytherapy will be done on MRI.
Following structures will be processed for automation on CT
For Aim 2. The Investigator intend to employ machine learning for developing more robust normal tissue toxicity prediction models. Further advanced techniques like texture analysis of radiation dose maps and follow up tissue density will also be performed to develop predictive models of toxicity. By using our patient datasets, Investigator want to create a library of proton beam plans with the proton planning systems that will be available in department of radiation oncology and using the developed normal tissue complication plots available the information of achievable doses through protons can help in identifying patients who will benefit from proton therapy.
For Aim 3. Within this project Investigator intend to integrate staging, pathology and quantitative imaging texture features for response prediction and identification of "high risk cohort" in cervix cancer. Images and clinical data from patients that have MRI at baseline will be included The texture features can be used to categorise "good" and "poor responders" after chemoradiation. For the same cohort of patients the Investigator also have tissue available including results of additional biomarkers (like AKT,LICAM, PDL1,CD4 and CD8). The Investigator intend to first correlate difference in texture features and see if there is a pattern of different molecular features. In the second step imaging and molecular features could be integrated for developing" risk prediction models". GTV and HRCTV delineated on 150 data sets at baseline and brachytherapy within Aim 1 will be utilised to categorise responders and non-responders and validate another 150 patient data sets.
Cervical cancer patients treated within ongoing and completed clinical trials of chemoradiation and brachytherapy for cervix cancer at our institute with access to MRI/CT images at time of diagnosis and brachytherapy, undergoing postoperative or definitive radiotherapy and treated within trials of postoperative or definitive RT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Aim 1 and Aim 3:
Exclusion Criteria:
Generation of software for automated target delineation for cervix cancer
1\. To develop and validate automated platforms for target delineation and planning for cervix cancer in time efficient manner through a. Machine learning based detection of abnormal cancerous tissues in multimodality medical diagnostic images. b . To train machine base systems for automated planning of external radiation and brachytherapy for gynaecological cancers.
Time frame: 3 years
Development and validation of Normal Tissue Complication Plots
2\. To use existing databases and radiation dose maps, imaging texture features and adverse events data for machine learning to develop "normal tissue complication plots "and to identify cervix cancer patient subgroups that may benefit from advanced radiation techniques (like proton treatment)
Time frame: 3 years
Identify "high risk patient population" that may benefit from intensification of treatment in future
3\. To use advanced image texture analysis within ongoing institutional and collaborative clinical trials to identify "high risk patient population" that may benefit from intensification of treatment in future
Time frame: 3 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Feb 2022 (actual). Primary completion is estimated for Jun 2026, 52 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tata Memorial Hospital